SCHEMBL17880574

SCHEMBL17880574

Cc1cc(F)c(Br)cc1-n1cnc(C2CC2)c1

nearest known ligand 0.53

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 20/20 0.53
MAP3K6 O95382 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18027905 0.87 MAP3K5 (0.55) MAP3K5MAP3K6
SCHEMBL29978259 0.84 MAP3K5 (0.53) MAP3K5MAP3K6
SCHEMBL28391289 0.84 MAP3K5 (0.53) MAP3K5MAP3K6
SCHEMBL23865350 0.83 MAP3K5 (0.40) MAP3K5MAP3K6
SCHEMBL23865466 0.83 MAP3K5 (0.44) MAP3K5MAP3K6
SCHEMBL22642547 0.82 MAP3K5 (0.51) MAP3K5MAP3K6
SCHEMBL22096504 0.82 MAP3K5 (0.53) MAP3K5MAP3K6
SCHEMBL22601537 0.82 MAP3K5 (0.51) MAP3K5MAP3K6
SCHEMBL20557293 0.81 MAP3K5 (0.53) MAP3K5MAP3K6
SCHEMBL15135934 0.81 MAP3K5 (0.50) MAP3K5MAP3K6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4276095-A2 PROCESSES FOR PREPARING ASK1 INHIBITORS Gilead Sciences, Inc. (US) 2023-11-15 EP disclosed
US-11814382-B2 Crystal form as ASK1 inhibitor and preparation method and application thereof FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) 2023-11-14 US disclosed
US-11814382-B2 Crystal form as ASK1 inhibitor and preparation method and application thereof FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) 2023-11-14 US disclosed
EP-3693366-B1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES INC (US) 2023-06-28 EP disclosed
US-20220135527-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. 2022-05-05 US disclosed
EP-3825315-A1 CRYSTAL FORM AS ASK1 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF Fujian Cosunter Pharmaceutical Co., Ltd. (CN) 2021-05-26 EP disclosed
EP-3237404-B1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES INC (US) 2020-11-11 EP disclosed
US-20200283393-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. 2020-09-10 US disclosed
EP-3693366-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS Gilead Sciences, Inc. (US) 2020-08-12 EP disclosed
WO-2020015721-A1 CRYSTAL FORM AS ASK1 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF 福建广生堂药业股份有限公司 2020-01-23 WO disclosed
US-20180022708-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. 2018-01-25 US disclosed
US-9771328-B2 Processes for preparing ASK1 inhibitors GILEAD SCIENCES, INC. (US) 2017-09-26 US disclosed
US-9771328-B2 Processes for preparing ASK1 inhibitors GILEAD SCIENCES, INC. (US) 2017-09-26 US disclosed
US-20170233350-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. 2017-08-17 US disclosed
US-20170233350-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. 2017-08-17 US disclosed
US-9586933-B2 Processes for preparing ASK1 inhibitors GILEAD SCIENCES, INC. (US) 2017-03-07 US disclosed
US-9586933-B2 Processes for preparing ASK1 inhibitors GILEAD SCIENCES, INC. (US) 2017-03-07 US disclosed
US-20160244430-A1 Processes for preparing ASK1 inhibitors GILEAD SCIENCES, INC. (US) 2016-08-25 US disclosed
US-20160244430-A1 Processes for preparing ASK1 inhibitors GILEAD SCIENCES, INC. (US) 2016-08-25 US disclosed
WO-2016106384-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS GILEAD SCIENCES, INC. (US) 2016-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11814382-B2 Crystal form as ASK1 inhibitor and preparation method and application thereof MLKL, MAP3K1, MAP3K19 MAP3K5 9/4885MAP3K6 6/4885
US-20170233350-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS MAP3K1, MAP3K6, MAP3K7 MAP3K5 6/4885MAP3K6 2/4885
US-20200283393-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS MAP3K1, MAP3K6, MAP3K7 MAP3K5 6/4885MAP3K6 2/4885
US-20180022708-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS MAP3K1, MAP3K6, MAP3K7 MAP3K5 6/4885MAP3K6 2/4885
US-20160244430-A1 Processes for preparing ASK1 inhibitors MAP3K1, MAP3K6, MAP3K7 MAP3K5 6/4885MAP3K6 2/4885
US-20220135527-A1 PROCESSES FOR PREPARING ASK1 INHIBITORS MAP3K1, MAP3K6, MAP3K7 MAP3K5 6/4885MAP3K6 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.